Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Exercise & healthspan
Research brief

Mouse muscle study compares transcription factor activity in spaceflight, aging and disuse atrophy

In three mouse muscle datasets, a small set of transcription factors changed across spaceflight, aging and disuse atrophy, while most differed by condition. [1]

Automatic summary · not editorially reviewed

The key findings

  1. Three mouse muscle datasets were analyzed: spaceflight versus ground control tibialis anterior, 28- versus 8-month-old gastrocnemius, and ten-day hindlimb unloading versus weight-bearing gastrocnemius. [1]

  2. Of 732 transcription factors scored, 47 were pan-atrophy, 161 partial and 295 condition-specific. [1]

  3. Correlation of transcription factor activity was highest between spaceflight and disuse atrophy and lowest between spaceflight and sarcopenia. [1]

The source at a glance

Study type / format
Comparative transcriptomic analysis (abstract)
Population / context
Mice: spaceflight versus ground control, 28- versus 8-month-old, and hindlimb-unloaded versus weight-bearing animals.
Summary based on
Study abstract
Original publication
October 1, 2026

Three mouse muscle datasets compared

The analysis used three mouse transcriptomic datasets. One was NASA OSD-576 (Rodent Research-23) tibialis anterior muscle from spaceflight versus ground control animals. A second was GSE145480 gastrocnemius muscle from 28-month-old versus 8-month-old mice, used as a sarcopenia model. The third was GSE273092 gastrocnemius muscle from mice after ten days of hindlimb unloading versus weight-bearing controls, a disuse atrophy model. Gene-level statistics were used to infer transcription factor activity against a mouse regulon of 43,226 factor-target interactions covering 1,165 factors.

Supporting source [1]

Shared and condition-specific regulators in mice

Of 732 transcription factors scored, 47 (6.4%) were classified as pan-atrophy, 161 (22.0%) as partial and 295 (40.3%) as condition-specific. Pan-atrophy regulators included the glucocorticoid receptor Nr3c1, Foxo1, the chromatin remodeller Smarca4 and the stress regulators Pml and Ing4. Stat1 crossed the threshold but showed a sign-discordant pattern: repressed in spaceflight and disuse but activated in sarcopenia. Spaceflight showed repression of Hsf1/Hsf2/Hsf4 and activation of Hdac7; sarcopenia uniquely activated Spi1, Stat5a and Irf2; disuse atrophy uniquely activated Mlxipl and Ovol1.

Supporting source [1]

Correlation patterns and abstract-only scope

The correlation of transcription factor activity profiles was highest between spaceflight and disuse atrophy (r = 0.4573) and lowest between spaceflight and sarcopenia (r = 0.1459). The authors describe a small but biologically coherent set of pan-atrophy regulators dominated by glucocorticoid and FoxO signaling, alongside a larger pool of condition-specific regulators. These are inferred transcription factor activities from mouse transcriptomic data, not measured protein activity or human outcomes. Only the abstract was reviewed; the full text was not reviewed, so methods and limitations beyond the abstract are unknown.

Supporting source [1]

How to interpret this

Abstract only; the full text was not reviewed. Findings are inferred transcription factor activities from mouse transcriptomic datasets, not measured protein activity or human outcomes.

Based on the study abstract; the full paper, tables and supplementary data were not reviewed.

Source & supporting passages

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    Three mouse transcriptomic datasets were analyzed
  2. Finding 2 ↑

    Of 732 TFs scored, 47
  3. Finding 3 ↑

    highest between spaceflight and disuse atrophy

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…